Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMS6E9J)

• Drug Name: Lefitolimod Drug Info
• Synonyms: MGN1703

Indication

Disease Entry	ICD 11	Status	REF
Human immunodeficiency virus-1 infection	1C62	Phase 2	[1]

• Cross-matching ID: TTD Drug ID: DMS6E9J

Molecule-Related Drug Atlas

Drug(s) Targeting Toll-like receptor 9 (TLR9)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cadi-05	DMPTCYB	Prostate cancer	2C82.0	Phase 3	[3]
SD-101	DMAMTGI	Hepatitis C virus infection	1E51.1	Phase 3	[4]
MGN-1703	DMCJRL1	Colorectal cancer	2B91.Z	Phase 3	[5]
IMO-2125	DM735FA	Melanoma	2C30	Phase 3	[6]
Tilsotolimod	DMGYK2N	Melanoma	2C30	Phase 3	[7]
MIS-416	DM7K4YR	Autoimmune diabetes	5A10	Phase 2	[8]
IMO-3100	DMM549D	Psoriasis vulgaris	EA90	Phase 2	[9]
BL-7040	DMSBPJI	Inflammatory bowel disease	DD72	Phase 2	[10]
CYT003	DM4LJH8	Asthma	CA23	Phase 2	[11]
CpG-10101	DM6MUCX	Hepatitis C virus infection	1E51.1	Phase 2	[12]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Toll-like receptor 9 (TLR9)	TTSHG0T	TLR9_HUMAN	Agonist	[2]

References

• [1] ClinicalTrials.gov (NCT03837756) Combining TLR9 Agonist With bNAbs for Reservoir Reduction and Immunological Control of HIV (TITAN). U.S. National Institutes of Health.
• [2] Beneficial modulation of the tumor microenvironment and generation of anti-tumor responses by TLR9 agonist lefitolimod alone and in combination with checkpoint inhibitors. Oncoimmunology. 2019 Sep 20;8(12):e1659096.
• [3] Trial Watch: Experimental Toll-like receptor agonists for cancer therapy. Oncoimmunology. 2012 August 1; 1(5): 699-716.
• [4] Novel drugs targeting Toll-like receptors for antiviral therapy. Future Virol. 2014 September; 9(9): 811-829.
• [5] Maintenance treatment with the immunomodulator MGN1703, a Toll-like receptor 9 (TLR9) agonist, in patients with metastatic colorectal carcinoma and disease control after chemotherapy: a randomised, double-blind, placebo-controlled trial. J Cancer Res Clin Oncol. 2014 Sep;140(9):1615-24.
• [6] Clinical pipeline report, company report or official report of Idera Pharmaceuticals (2011).
• [7] Tilsotolimod with ipilimumab drives tumor responses in anti-PD-1 refractory melanoma. Cancer Discov. 2021 Mar 11;candisc.1546.2020.
• [8] DOI: 10.1371/journal.pone.0087712
• [9] Company report (Iderapharma)
• [10] Gut feeling: MicroRNA discriminators of the intestinal TLR9-cholinergic links. Int Immunopharmacol. 2015 Nov;29(1):8-14.
• [11] CYT003, a TLR9 agonist, in persistent allergic asthma - a randomized placebo-controlled Phase 2b study. Allergy. 2015 Sep;70(9):1160-8.
• [12] Safety, pharmacokinetics and immune effects in normal volunteers of CPG 10101 (ACTILON), an investigational synthetic toll-like receptor 9 agonist. Antivir Ther. 2007;12(5):741-51.